august investor briefing, page-3

As I stated before.. Until ph3 funding and Fonda revenues are confirmed, there is no reason to jump into the stock. As it seems Fonda revenues are well short hence no way this can fund ph3. CR most likely path foward, I would guess around 15-20c. Mgt kills the sp once again.

Important to note, Gsk could kill Fonda by reducing it's price for AG which might result in DRL dropping Fonda... Worst case yes but far from impossible